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Abstract Liver cirrhosis is a disease with an increasing incidence. Surgical procedures in 
patients with cirrhosis are also increasing, due to a longer life expectancy in these 
patients and also to the improvement of therapeutic and diagnostic resources.  
Digestive hemorrhage in the cirrhotic patient requires emergency medical 
intervention (intensive therapy, endoscopic or even surgical approaches), being at the 
same time a factor that precipitates episodes of encephalopathy, i.e. the conventional 
complication of cirrhosis. Hepatic encephalopathy represents one of the most severe 
clinical events of cirrhosis, being associated with high morbidity and mortality. The 
causes of hepatic encephalopathy are briefly presented in this paper. Therapeutic 
approaches currently available consist in the administration of non-absorbable 
disaccharides such as lactulose and non-absorbable antibiotics such as rifaximin. New 
therapeutic perspectives are under evaluation, e.g. ammonia scavengers and the 
modulation of gut microbiota. 
Clotting disorders in patients with liver cirrhosis are more severe as the disease 
progresses and involves complex mechanisms, as presented in this review. The 
correction of possible disorders of hemostasis should be promptly made as a sine qua 
non condition prior to surgery.     
Keywords  liver cirrhosis, hemostasis, hypocoagulability, hypercoagulability, bleeding, 
encephalopathy. 
Highlights  It is difficult to determine the hemostatic profile of cirrhotic patients only by running the 
usual laboratory tests, due to the existence of a fragile balance between hypo- and 
hypercoagulability factors. 
 Most cases of hepatic encephalopathy are precipitated by events such as digestive 
hemorrhage and infections, which must be carefully monitored to prevent 
encephalopathy in cirrhotic patients as much as possible.    
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Introduction 
In the last decades, there has been a spectacular 
increase in the life expectancy of patients with liver 
cirrhosis thanks to the improvement of therapeutic and 
diagnostic resources. On the background of these data, but 
also because of the increase in cirrhotic incidence, the 
number of surgical procedures in patients with cirrhosis is 
also increasing. Due to limited cases that are suited for 
liver transplantation, the medical and surgical therapeutic 
approaches focus especially on complications, which have 
become the main concern of the long-term management 
of cirrhosis (1). 
 One of the mandatory requirements for the cirrhotic 
patient who is about to undergo surgery is the evaluation 
of the hemostatic profile, since liver cirrhosis is 
accompanied by clotting disorders that increase as the 
disease progresses. The correction of the possible 
disorders of hemostasis should be promptly made as a 
sine qua non condition prior to surgery (2). 
 Clinically, hemostatic disorders are revealed by the 
presence of bruises, purpura, epistaxis or gingivorrhagia. 
Hemostatic abnormalities in cirrhosis are multifactorial. 
They are a consequence of the decreasing capacity of 
hepatocyte synthesis, reticuloendothelial dysfunction and 
portal hypertension (3). 
Hepatic encephalopathy (HE) is a relatively frequent 
complication encountered especially in the advanced 
stages of cirrhosis. HE is expressed through several 
(neuropsychiatric, neuromuscular, metabolic etc.) 
dysfunctions. According to literature, minor HE affects up 
to 60-70% of patients with cirrhosis to a certain extent. 
Although many patients with minor HE (subtle alterations 
of the cognitive functions) seem to be clinically 
asymptomatic, the condition has a considerable impact on 
the patients’ life quality, such as poor driving 
performance, an increased risk of falls, predispositions to 
hospitalizations and even death (4). 
Severe HE usually implies more severe signs and 
symptoms, represented by alterations in consciousness, 
temporal and spatial disorientation, behavioral and 
emotional changes, and generalized motor dysfunction. 
During its evolution, this form of HE is encountered in 
about 30–45% of patients with cirrhosis, representing a 
significant cause of hospitalizations for patients with poor 
evolution and prognosis (5).  
Possible precipitating factors of HE are 
gastrointestinal bleedings, bacterial infections, and 
accumulation of gut-derived toxins (especially ammonia). 
All these factors (causing inflammation and oxidative 
stress) lead to cerebral edema, which underlies the core 
symptoms of HE (6). 
Discussions 
For a long time, it has been assumed that the decrease 
in circulating platelets is due to hypersplenism. In 1967, 
Aster and Jandl correlated splenomegaly in portal 
hypertension with extensive platelets pooling which 
would cause thrombocytopenia (1, 3). 
However, this assumption does not explain all the 
platelet changes and it is contradicted by a few 
observations. Splenomegaly in cirrhosis is not in a linear 
relation with the degree of portal hypertension, but it is 
rather the effect of parenchymal hypertrophy. On the 
other hand, surgical procedures to reduce portal 
hypertension, such as portacaval shunt, do not directly 
lead the increase of circulating platelet count (4, 5).  
Radio labeled platelet studies showed that there is a 
shortening of the life span of platelets in liver cirrhosis. 
Thrombocytolysis occurs through an immunological 
mechanism proven by the presence of increased 
concentrations of autoantibodies in the serum against a 
major platelet antigen, GP IIb / IIIa. These antibodies are 
produced by B lymphocytes, the proportion of which 
increases (7). 
Maintenance of platelet counts within normal limits 
depends on the ability of bone marrow to increase 
production, which is reflected in the proportion of young 
elements in the circulation. Although thrombocytopoiesis 
is under the direct effect of thrombopoietin, a growth 
factor synthesized mainly by the liver and the kidney, and 
whose serum levels decrease in advanced cirrhosis and 
portal hypertension, its titers do not correlate directly with 
medullary platelets synthesis (8).  
This apparent discordance results from the fact that 
the removal of thrombopoietin from the circulation is 
made through its internalization in megakaryocytes and 
platelets, including those which are pooled in the spleen 
(9). In liver cirrhosis, platelets also show quantitative 
changes besides decreasing in number (10). 
The observed hypo-aggregability has complex 
mechanisms, which include both platelet factors and 
plasma factors. On the one hand, there is a 
transmembrane signaling the defect after stimulation with 
thrombin or collagen and thus a decrease in intracellular 
messengers, and, on the other hand, a number of plasma 
factors that have a negative effect on aggregability. The 
latter includes: bile salts, fibrinogen degradation products, 
HDL or apolipoprotein E (6-8). 
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Preoperative thrombocytopenia requires correction by 
platelet transfusion to achieve a platelet level which can 
be considered safe depending on the type of surgical 
intervention. Minor surgical procedures with a low 
bleeding risk can be safely performed with platelet count 
>50 000/mm3, while major surgery requires a minimum 
platelet count of 100,000/mm3 (11). 
Coagulation disorders in the cirrhotic patient may 
occur not only in the context of quantitative and 
qualitative changes in platelets, but also in the reduction 
of coagulation factors. Most of them are synthesized in 
the hepatocyte, except factor VIII (12). 
The usual laboratory tests, prothrombin time (PT) and 
activated partial thromboplastin time (APTT), indicate a 
degree of hypercoagulability in patients with advanced 
diseases, but they do not objectively reflect their 
hemostatic profile. Recent studies suggest that there is a 
balance, albeit precarious in cirrhosis, between hypo- and 
hypercoagulability resulting from deficiencies in the 
synthesis of both pro-coagulant and anti-coagulant factors 
(13, 14). 
In cirrhosis, there is a deficiency in the synthesis of 
vitamin K-dependent coagulation factors, II, VII, IX and 
X, which result from the decrease in hepatocyte 
production capacity and from the decrease in vitamin 
absorption in the intestinal lumen due to the antibiotic 
treatment which reduces the bacterial flora that produces 
it, the decrease in vitamin K synthesis or cholestasis (15). 
Besides, there are also abnormalities of fibrinolysis 
due to the alteration of the synthesis of fibrinolytic 
factors, but also their clearance, for which the 
reticuloendothelial system of the liver is mainly 
responsible. Thus, one can see an imbalance between the 
plasminogen tissue activator and its inhibitor PAI1, 
resulting in a fibrinolysis deficiency which is amplified by 
a decreased clearance of circulating activated coagulation 
factors (16). 
The protein synthesis deficiency also influences the 
production of anticoagulant factors, especially protein C 
and its cofactor, protein S, whose role in vivo is to reduce 
thrombin production by inhibiting Factors Va and VIIa 
(17). 
Given the apparent hypocoagulability present in 
cirrhosis, which can be revealed by the usual laboratory 
tests, PT and APTT, it is considered that this category of 
patients is somewhat “protected” against the risk of 
thrombosis (16, 18). 
However, clinical observations show a considerable 
incidence of thrombosis in advanced cirrhosis, especially 
in portal and mesenteric veins. In addition to 
hypercoagulability, whose causes have been exposed 
above, Virchow Triad is complemented by hemodynamic 
changes in these cases, consisting in slowing down the 
blood flow through portal hypertension and vascular wall 
alterations (19). 
In addition, there are factors that further contribute to 
the progression of hepatic cirrhosis such as the formation 
of intraparenchymatous microthrombi caused by ischemia 
and the activation of stellate cells by thrombin (20). 
The deficiencies of the factors involved in hemostasis 
affect all its sequences, which leads to the occurrence of 
balance, but more fragile than in normal conditions, 
between hypo- and hypercoagulability: the procoagulant 
protein deficiency is offset due to the deficiency of 
proteins C and S, fibrinolysis is balanced by the 
concomitant deficiency of antifibrinolytics and the 
qualitative and quantitative deficiencies of platelets are 
offset by the increase in plasma levels of von Willebrand 
factor and a protein which stimulates platelet adhesion 
(21, 22). 
The hemostatic profile of cirrhotic patients is therefore 
difficult to determine only by running the usual laboratory 
tests, but given the experience of liver transplantation 
centers, one can recommend major surgery even in 
patients with cirrhosis who are apparently in a state of 
hypocoagulability, without the risk of major incidents 
(14). Until the validation of these data, in patients 
undergoing surgery, the correction of coagulation deficits 
is practically mandatory (23). 
Enteric bacterial translocation is favored in patients 
with cirrhosis, being influenced by immunological 
impairment/ presence of intestinal bacterial overgrowth, 
and increased intestinal permeability. This bacterial 
translocation increases the levels of systemic gut-derived 
toxins (especially in the presence of portosystemic shunt), 
thus having an important role in the development of HE. 
Moreover, bacterial translocation increases the risk of 
abdominal infection (bacterial peritonitis, septicemia), 
which negatively influence morbidity and mortality in 
patients with cirrhosis (24, 25).  
Although the pathophysiological mechanisms 
involved in hepatic encephalopathy (HE) are not yet fully 
elucidated, literature data show that an increased 
accumulation of gut-derived toxins (ammonia and other 
derivatives), represents the main factors which determine 
HE. The accumulation of toxins (from bacteria, 
inflammation and oxidative stress) is the consequence of 
decreased liver function on one hand, and due to 
development of portosystemic shunts (which diminish the 
liver capacity to remove toxins from the blood-stream) on 
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the other hand. All these mechanisms are responsible (at 
least in part) for cerebral edema, which represents the 
main substrate of HE (26). 
Most cases of hepatic encephalopathy are precipitated 
by events such as digestive hemorrhage, 
hydroelectrolytic/ acido-basal imbalance, infections, 
sedation, constipation or diarrhea, etc. This means that a 
good monitoring/ control of the hemostatic profile of 
cirrhotic patients can reduce the rate of digestive bleeding 
in these patients, and thus reduces the number/severity of 
hepatic encephalopathies (27-29). 
Conclusions 
Hemostasis disorders in patients with liver cirrhosis 
have complex mechanisms and are more severe in the 
advanced stages of the disease. In patients with cirrhosis, 
there is a relative precarious balance between hypo- and 
hypercoagulability, which is caused by deficiencies in the 
synthesis of both procoagulant and anti-coagulant factors. 
Hepatic encephalopathy, variceal bleeding, jaundice 
and ascites, are diagnostic elements of decompensated 
cirrhosis, which is associated with high mortality rates if 
the patient does not benefit from liver transplantation. 
Decompensated cirrhosis should be delineated by acute-
on-chronic liver failure (ACLF), represented by a chronic 
liver disease (in patients with or without cirrhosis) that 
presents a rapid decline (hepatic and extra-hepatic organ 
failures) due to the intervention of several precipitating 
factors. 
The risk of bleeding is correlated with the type of 
surgery in cirrhotic patients, but prior to the surgical 
procedure it is mandatory to correct the clotting disorders 
in order to minimize the risk of intraoperative bleeding. 
For this purpose, the already existing diagnostic, 
monitoring and treatment protocols for cirrhotic patients 
should be improved. For example, a very recent protocol 
for end-stage liver disease proved to be able to evaluate 
morbidity and mortality more accurately than the older 
prognostic models in cirrhotic patients (30). 
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